Complete Guide to Tirzepatide: Everything You Need to Know

Quick Answer: Tirzepatide is a dual GIP/GLP-1 receptor agonist medication. FDA-approved versions (Mounjaro, Zepbound) demonstrated significant weight loss in clinical trials. Important: Compounded tirzepatide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications. Individual results vary significantly and are not guaranteed. Clinical trial data applies only to FDA-approved brand-name medications and may not apply to compounded tirzepatide. Tirzepatide carries an FDA boxed warning for possible thyroid C-cell tumors; discuss your risk with your clinician.

What Is Tirzepatide?

Tirzepatide is a weight management medication that represents a newer class beyond semaglutide and other GLP-1 medications. While semaglutide mimics one hormone (GLP-1), tirzepatide is a dual-action medication that mimics both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The direct comparison discussed below concerns semaglutide in adults with obesity without type 2 diabetes.

Originally developed for type 2 diabetes treatment, tirzepatide is available as FDA-approved Mounjaro and Zepbound. Important: Compounded tirzepatide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications. Clinical trial data applies only to FDA-approved brands and may not apply to compounded tirzepatide.

Brand Names and Availability

Mounjaro®: FDA-approved for type 2 diabetes (May 2022)

• Manufactured by Eli Lilly
• Available in six dose strengths (2.5 mg to 15 mg); see Mounjaro prescribing information, section 3
• Often prescribed off-label for weight loss

Zepbound®: FDA-approved for chronic weight management (November 2023)

• FDA-approved for weight loss
• Specifically approved for weight loss in adults with obesity or overweight with weight-related conditions
• Available in 6 dose strengths (2.5 mg to 15 mg)

Compounded Tirzepatide: Available from specialized compounding pharmacies

• Compounded tirzepatide is NOT FDA-approved
• NOT FDA-approved - FDA does not verify safety or effectiveness
• Regulatory status may change - consult healthcare provider
• Clinical trial data applies only to FDA-approved products, not compounded versions

How Tirzepatide Works

Tirzepatide activates GIP and GLP-1 receptors. Zepbound prescribing information, sections 12.1–12.2, describes reduced calorie intake, likely through effects on appetite. Some evidence about GIP’s contribution to food-intake regulation comes from nonclinical studies.

Tirzepatide stimulates insulin release in a glucose-dependent manner and reduces glucagon secretion. The label also reports improved insulin sensitivity in a study of people with type 2 diabetes. It delays stomach emptying; that effect is strongest after the first dose and diminishes over time.

The label describes greater loss of fat mass than lean mass, which does not mean muscle loss is prevented. A mechanism alone cannot establish how much weight someone will lose, prove superiority over every other medication or establish the effects of compounded formulations. The clinical studies below address specific outcomes and populations.

How Effective Is Tirzepatide for Weight Loss?

The direct comparison discussed below concerns semaglutide in adults with obesity without type 2 diabetes. The figures below come from trials of FDA-approved tirzepatide (Mounjaro, Zepbound). Individual results vary, are not guaranteed, and may not apply to compounded tirzepatide.

SURMOUNT Clinical Trial Results (FDA-Approved Tirzepatide)

SURMOUNT-1 studied adults with obesity or overweight with a weight-related condition, without type 2 diabetes, over 72 weeks. The table below uses the intention-to-treat analysis reported as Study 1 in Zepbound prescribing information, section 14.1, Table 2. It includes all randomized participants and statistical estimates for missing weight measurements. At 15 mg, the estimated average weight reduction was 20.9%, compared with 3.1% for placebo. These results do not establish outcomes for compounded tirzepatide; individual results vary.

Randomized Trial Group	Mean Weight Reduction at 72 Weeks	Participants Losing at Least 20%
5 mg	15.0% of body weight	30.0%
10 mg	19.5% of body weight	50.1%
15 mg	20.9% of body weight	56.7%
Placebo	3.1% of body weight	3.1%

The dose labels identify trial groups, not a dosing recommendation. These estimates account for missing observations; they are not simply averages among people who completed treatment. Different analyses of the same trial can produce different estimates. The former table did not identify its analysis; this version uses the labeled intention-to-treat results consistently.

What These Percentages Can Mean (Illustrative Only)

SURMOUNT-1 reported these averages as a percentage of starting body weight, in participants taking FDA-approved tirzepatide:

• 10 mg trial average: about 19.5% of starting body weight
• 15 mg trial average: about 20.9% of starting body weight

These are trial averages, not predictions. Individual results vary, are not guaranteed, and may not apply to compounded tirzepatide, which has not been studied in these trials. Working an average into a pound figure for your own starting weight is not what the data supports — what any individual experiences depends on factors the trial averages do not capture.

How FDA-Approved Tirzepatide Compared to Other Treatments in Trials

SURMOUNT-5 directly compared weekly tirzepatide and semaglutide in 751 adults with obesity without type 2 diabetes. At 72 weeks, estimated average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. Participants received the maximum dose they tolerated within the trial’s specified options.

The trial was randomized and open-label, and Eli Lilly funded it. Its results concern the regimens and population studied; they do not establish superiority over every weight-management medication, predict an individual’s response or establish outcomes for compounded formulations.

Beyond Weight Loss: Additional Health Markers

The selected results below come from Study 1 in Zepbound prescribing information, section 14.1, Table 3: adults with obesity or overweight, without type 2 diabetes, assessed at 72 weeks using the intention-to-treat population.

Marker: Change From Baseline	Placebo	5 mg	10 mg	15 mg
Systolic blood pressure (mmHg)	-1.0	-6.6	-7.7	-7.4
LDL cholesterol (%)	-1.7	-4.6	-5.6	-7.1
Triglycerides (%)	-5.6	-21.2	-23.8	-29.1

These are within-group changes, not placebo-adjusted treatment effects. The lipid rows show percentage changes, not percentage-point changes. They do not establish that every patient will improve or that compounded tirzepatide produces the same outcomes. Changes in these markers alone are not evidence of fewer heart attacks, longer life or a reason to change other medication. Discuss your own results with your clinician.

Tirzepatide vs Semaglutide: Key Differences

Both medications are used for weight management. In the SURMOUNT-5 head-to-head trial of the FDA-approved branded products (Zepbound and Wegovy), tirzepatide produced greater average weight loss than semaglutide (Aronne LJ et al., N Engl J Med, 2025, doi:10.1056/NEJMoa2416394). These comparisons apply to FDA-approved products and may not apply to compounded versions of either drug. Compounded tirzepatide and compounded semaglutide are not FDA-reviewed, are not generics, and are not equivalent to or interchangeable with the branded products these trials studied. Important differences to consider:

Feature	Tirzepatide	Semaglutide
Mechanism	Dual GIP/GLP-1 agonist	GLP-1 agonist only
Average Weight Reduction at 72 Weeks in SURMOUNT-5	20.2%	13.7%
Highest Doses Studied in SURMOUNT-5	15 mg weekly	2.4 mg weekly
Brand Cost	$1,060-1,200/month	$1,350-1,600/month
Dosing	Once weekly injection	Once weekly injection

Nausea percentages from separate trials do not establish which medication is easier to tolerate. Zepbound prescribing information, section 6.1, cautions against directly comparing adverse-reaction rates across different drugs’ trials. The previous nausea-rate row did not identify its sources and has been removed. A weight-loss comparison alone does not establish a tolerability advantage.

When to Discuss Tirzepatide With Your Clinician

Medication selection depends on weight-related health needs, medical history, other medicines and potential adverse effects. NIDDK’s guidance describes BMI and associated health conditions as considerations; a target number of pounds to lose is not a substitute for clinical assessment. Discuss a plateau or previous treatment response with your prescriber rather than assuming it establishes which medicine to use next.

The right medication depends on your health history, goals, and your clinician’s judgment. For a detailed comparison of effectiveness, side effects, and costs, see our comprehensive tirzepatide vs semaglutide comparison.

Who Qualifies for Tirzepatide?

FDA-Approved Indications

Zepbound (Weight Loss):

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related health condition:
  • High blood pressure
  • Type 2 diabetes
  • High cholesterol
  • Obstructive sleep apnea
  • Cardiovascular disease
• Age 18 or older

Mounjaro (FDA-Approved Branded Product):

The August 2026 Mounjaro prescribing information, section 1, lists two indications:

• Improving blood sugar control alongside diet and exercise in adults and children aged 10 years and older with type 2 diabetes.
• Reducing major cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

These are Mounjaro’s labeled indications. They do not establish eligibility for Boca care or approval of compounded tirzepatide. Whether a particular treatment is appropriate requires a licensed clinician’s evaluation.

Who Should NOT Use Tirzepatide

Zepbound contraindications (prescribing information, section 4):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A previous serious hypersensitivity reaction to tirzepatide or an ingredient in Zepbound

Pregnancy and breastfeeding require separate consideration. Zepbound labeling directs discontinuation when pregnancy is recognized. Discuss pregnancy planning with your prescriber before trying to conceive. During breastfeeding, the label calls for weighing maternal clinical need, breastfeeding benefits and potential infant risks; limited milk-concentration data do not establish infant safety. See sections 8.1–8.2 of the prescribing information.

Oral hormonal contraception: Zepbound may reduce its effectiveness. The label recommends a non-oral method or added barrier protection for four weeks after starting and after each dose increase. Discuss this with your prescriber. See sections 7.2 and 8.3.

Tirzepatide carries an FDA boxed warning for possible thyroid C-cell tumors based on animal studies; it is contraindicated in people with a personal or family history of MTC or MEN 2. See the Safety and Contraindications section below for full details.

Other warnings and conditions to discuss:

These are not interchangeable with the contraindications above. Zepbound labeling, sections 5.2–5.5 and 5.8, describes gastrointestinal, kidney, gallbladder, pancreatic and diabetic eye-disease risks:

• Zepbound is not recommended for people with severe gastroparesis.
• Vomiting or diarrhea can cause dehydration and kidney injury; kidney-function monitoring may be needed.
• Report a history of pancreatitis or gallbladder problems to your prescriber. Suspected pancreatitis requires stopping treatment and prompt medical assessment.
• People with a history of diabetic retinopathy need monitoring for progression.

This is not a complete safety checklist. The kidney-disease discussion below explains the label’s separate dosing guidance.

Special Populations

Older adults: Zepbound labeling, section 8.5, reports no overall safety or effectiveness differences between older and younger adults in the weight-reduction studies. Relatively few participants were 75 or older; individual assessment remains important.

Kidney disease: Section 8.6 does not recommend a dose adjustment for renal impairment and includes pharmacokinetic findings in end-stage renal disease. It calls for kidney-function monitoring when adverse reactions could cause dehydration. This does not mean treatment is appropriate for every patient with kidney disease; discuss your situation with your prescriber.

How to Use Tirzepatide

Product-Specific Instructions

Tirzepatide products and injection devices differ. Zepbound labeling, section 2.4, calls for training appropriate to the prescribed presentation, including when it changes. Follow the supplied instructions for administration and storage; a pen’s steps should not be applied to a vial or another device.

Ask your pharmacist to clarify any unfamiliar device, concentration, storage instruction or discard date before use. Compounded preparations require instructions from the dispensing pharmacy.

What if you miss a dose?

• Contact your Boca clinician or pharmacist before taking a missed dose. Do not decide on your own whether to take it, skip it, or shift your schedule.
• Never double up doses.
• Follow your clinician’s guidance and the product instructions. For more, see our article on what to do if you miss a tirzepatide dose

Tirzepatide Dosing Schedule

Zepbound prescribing information, sections 2.1–2.2, distinguishes starting treatment from maintenance. The starting dose is not a maintenance dose. Later increases are conditional, with at least four weeks at the current dose before an increase; reaching the maximum is not required for everyone.

For weight reduction and long-term maintenance, the label lists 5 mg, 10 mg or 15 mg once weekly. The prescriber considers response and tolerability when selecting a maintenance dose. These are labeled options for Zepbound, not instructions to select or change your own dose, and not a dosing protocol for compounded tirzepatide.

Dosing Flexibility

Discuss progress and side effects with your clinician. A plateau alone does not establish that an increase is appropriate, and the label does not define an eight-week plateau as a trigger. Follow your prescription and contact your clinician before changing treatment.

For questions about interpreting progress, see our tirzepatide weight loss timeline guide.

Common Side Effects

The frequencies below come from the pooled Zepbound weight-management trials in adults with obesity or overweight, with or without type 2 diabetes. They are percentages within each study group, not predictions for an individual or established rates for compounded tirzepatide. Zepbound prescribing information, section 6.1, Table 1.

Reported Reaction	Placebo	Zepbound 5 mg	Zepbound 10 mg	Zepbound 15 mg
Nausea	8%	25%	29%	28%
Diarrhea	8%	19%	21%	23%
Vomiting	2%	8%	11%	13%
Constipation	5%	17%	14%	11%
Abdominal pain	5%	9%	9%	10%
Fatigue	3%	5%	6%	7%
Injection-site reactions	2%	6%	8%	8%

This is a selected list; the label contains additional reactions and grouped symptom definitions. The dose columns identify trial groups, not instructions for selecting a dose. Most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. That does not establish a fixed week when symptoms will resolve for an individual.

Serious reactions can occur. Seek immediate medical attention for severe, persistent abdominal pain or symptoms of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing. See Safety and Contraindications for the boxed warning and other precautions. Discuss persistent or concerning symptoms with your clinician; this table is not a complete safety assessment.

Managing Side Effects

For comprehensive strategies to manage tirzepatide side effects, including dietary recommendations and when to contact your doctor, see our complete guide to managing tirzepatide side effects.

Weight Loss Timeline

The SURMOUNT-1 results summarized above were assessed at 72 weeks, after dose escalation and maintenance treatment. Zepbound labeling, section 14.1, also shows average weight changes over time. A group-average curve does not set monthly targets for an individual, and the endpoint result should not be divided into a promised weekly rate.

The study population, treatment group and analysis matter when interpreting a timeline. Your clinician can assess your progress alongside tolerability and health needs. Do not increase a dose to catch up with a chart. Results vary, and the branded-product trials do not establish a timeline for compounded tirzepatide.

For related questions to discuss with your clinician, see our tirzepatide timeline guide.

Cost and Affordability

Cost is often a major consideration when discussing tirzepatide with your clinician.

Brand-Name Pricing

Medication	Monthly Cost (Without Insurance)	Annual Cost
Zepbound (weight loss)	$1,060-1,200	$12,720-14,400
Mounjaro (diabetes)	$1,025-1,150	$12,300-13,800

Insurance Coverage Reality

For Type 2 Diabetes (Mounjaro):

• Better coverage; many insurance plans cover with prior authorization
• Average copay with coverage: $25-$50/month
• Manufacturer savings card may be available

For Weight Loss (Zepbound):

• Very limited insurance coverage
• Most plans exclude weight loss medications
• Medicare doesn’t cover medications for weight loss
• Some employer plans may cover with specific criteria

Compounded Tirzepatide

Important: Compounded tirzepatide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications. Compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy that prepares your medication individually, for you, based on your prescription, but compounded products are not individually FDA-approved (registration is not the same as approval).

Typical Compounded Pricing:

• Monthly cost: see current pricing on our compounded tirzepatide page (flat pricing across all dose levels)
• Flat pricing regardless of dose

What’s Typically Included:

• Medication from a state-licensed compounding pharmacy
• All necessary supplies (needles, alcohol swabs, sharps container)
• Medical oversight and provider consultations
• Flat pricing regardless of dose

For a complete cost breakdown, insurance strategies, and ways to save, see our comprehensive tirzepatide cost guide.

Brand-Name vs Compounded Tirzepatide

How Do Brand-Name and Compounded Tirzepatide Differ?

This is one of the most common questions patients ask. Compounded tirzepatide is NOT FDA-approved, and clinical trial data applies only to the FDA-approved branded products. Here’s what to know:

Factor	Brand-Name	Compounded
Active Ingredient	Tirzepatide (FDA-approved formulation)	Tirzepatide (compounded; formulation, concentration and excipients may differ)
FDA Approval	Yes (Zepbound, Mounjaro)	No (NOT FDA-approved)
Clinical Evidence	The branded-product trials discussed above studied specific formulations and populations	Those trials do not establish outcomes for a compounded formulation; FDA does not review compounded drugs for safety, effectiveness or quality before marketing
Pharmacy Standards	FDA-regulated manufacturing	State-licensed compounding pharmacy (product not individually FDA-approved)
Quality Testing	Rigorous FDA standards	Third-party testing (potency, sterility) varies by pharmacy
Delivery Device	Zepbound labeling includes single-dose pens and vials, multi-dose vials and single-patient-use KwikPens	Follow the dispensing pharmacy’s instructions for the specific preparation and device
Cost	$1,000-1,200/month	See current pricing on our compounded tirzepatide page

Important: While the active ingredient is tirzepatide in both cases, compounded products are not FDA-approved and the safety and effectiveness data from the branded clinical trials cannot be assumed to apply to compounded tirzepatide. See FDA’s explanation of compounded-drug risks and Zepbound prescribing information, section 3, for its presentations.

About Compounding

Under the 503A pathway, a medication may be compounded for an individual patient when a clinician determines it’s appropriate. Other conditions also apply:

1. The legal and regulatory status of compounding is complex and subject to change
2. Discuss FDA-approved options with your healthcare provider
3. The medication must be prescribed by a licensed healthcare provider

Quality Considerations

Markers some patients look for when evaluating a provider:

• State-licensed compounding pharmacy
• Third-party potency testing (certificate of analysis provided)
• Sterility testing for batches
• Transparency about the manufacturing process
• Medical oversight included with the prescription

For detailed information about compounded tirzepatide quality standards and what to look for, see our complete compounded tirzepatide safety guide.

Safety and Contraindications

FDA Boxed Warning: Thyroid C-Cell Tumors

Tirzepatide carries an FDA boxed warning for possible thyroid C-cell tumors based on animal studies; the human risk is not determined. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Discuss your risk with your clinician.

What this means:

• Rodent studies showed increased thyroid C-cell tumors at certain doses
• Whether tirzepatide causes these tumors in humans has not been determined
• Do not use if: you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
• Report symptoms such as a neck mass, trouble swallowing, hoarseness, or shortness of breath to your clinician

Long-Term Safety: What Is Known So Far

Published follow-up now extends beyond two years. The 176-week SURMOUNT-1 report studied participants with obesity and prediabetes, followed by 17 weeks off treatment. That population and follow-up period must be kept explicit; the study does not establish indefinite safety or outcomes for compounded tirzepatide.

Published findings and ongoing research:

• The health-marker results above describe specific measured outcomes.
• SURMOUNT-MMO (NCT05556512) investigates morbidity and mortality. At our September 14, 2026 check, its registry listed it as active, not recruiting, with no posted results and an estimated October 2027 completion. The record was last updated January 12, 2026; that estimate is not a promised results date. Registration alone does not establish benefit or long-term safety.

Areas still being studied or monitored:

• Thyroid C-cell tumors (see boxed warning above)
• Pancreatitis (uncommon in trials)
• Long-term effects on bone density (limited data so far)
• Longer-term and real-world safety beyond the trial periods

Drug Interactions

Review all medicines and supplements with your prescriber. Zepbound labeling, sections 1 and 7, identifies these considerations:

• Insulin and insulin-releasing medicines such as sulfonylureas: Combining them with Zepbound increases low-blood-sugar risk. The prescriber may consider reducing those medicines; do not adjust them yourself.
• Oral medicines: Delayed stomach emptying can affect absorption. Some medicines, including warfarin, require monitoring because their effects depend on a narrow concentration range.
• Oral hormonal contraception: See the contraception guidance above for the label’s precautions after starting or increasing treatment.
• Other tirzepatide or GLP-1 products: The label does not recommend combining Zepbound with these products.

This summary is not an exhaustive interaction check. A medicine’s association with weight gain does not by itself establish that it reduces tirzepatide’s effectiveness or should be stopped.

Long-Term Use Considerations

Is Tirzepatide a Lifelong Medication?

For many people, tirzepatide is used as a long-term treatment. Your clinician can help you decide what is right for you. Here’s the context:

Weight Regain After Stopping:

• Research suggests many people regain a substantial portion of lost weight within about 12 months of stopping
• Appetite hormones tend to return to pre-treatment levels
• Metabolic adaptations may persist

Maintenance Dosing Strategies (Clinician-Directed):

• Some people maintain weight loss on lower “maintenance” doses
• Example: reducing the dose after reaching goal weight, if your clinician agrees
• May allow sustained benefits while reducing costs (if paying out-of-pocket)
• May reduce long-term side effects for some people

Alternatives to Lifelong Treatment:

• Intensive lifestyle modification (structured exercise and dietary adherence)
• Medication “holidays” with close monitoring (carries risk of regain)
• Transitioning to other clinician-recommended options for maintenance

What Happens When You Stop Tirzepatide?

For detailed information about weight regain patterns, tapering strategies, and how to maximize your chances of maintaining weight loss if you decide to stop, see our comprehensive guide on stopping tirzepatide.

How to Get Started with Tirzepatide

Steps to Begin Treatment

1. Consultation with Healthcare Provider

• Discuss your weight loss goals and medical history
• Review medications and health conditions
• Determine if you qualify for tirzepatide
• Discuss brand-name vs compounded options, including that compounded tirzepatide is not FDA-approved

2. Obtain Prescription

• Provider prescribes an appropriate starting dose if suitable for you
• Prescription sent to pharmacy or telehealth provider
• Insurance prior authorization submitted if applicable

3. Receive Medication and Supplies

• Medication shipped with necessary supplies
• Includes needles, alcohol swabs, sharps container
• Storage instructions provided
• Injection training resources available

4. First Injection

• Many people prefer their first injection with guidance
• Review injection technique
• Understand side effect management
• Schedule follow-up for dose escalation

For step-by-step injection instructions, see our detailed tirzepatide injection guide.

Telehealth Options

Tirzepatide is increasingly discussed through telehealth platforms. These platforms may offer:

Potential Advantages:

• Convenient online consultations
• Medication shipped to your home
• Ongoing provider support via messaging
• Compounded options at lower cost (not FDA-approved)
• No in-person visits required

What to Look For:

• Licensed healthcare providers (MD, DO, NP, PA)
• State medical licensure verification
• Transparent pricing
• State-licensed compounding pharmacy
• Ongoing medical supervision included
• Clear communication channels

Boca Health’s Tirzepatide Program

At Boca Health, we provide tirzepatide weight management services with medical oversight:

• Medical Oversight: Licensed providers experienced with weight management medications
• Compounded Tirzepatide: see current pricing on our compounded tirzepatide page; medication is prepared by a state-licensed 503A compounding pharmacy that prepares your medication individually, for you, based on your prescription (compounded tirzepatide is NOT FDA-approved)
• All Supplies Included: Needles, syringes, alcohol swabs, sharps container
• Ongoing Support: Regular check-ins and clinician-directed dose optimization
• Flexible Dosing: Personalized escalation based on your tolerance and your clinician’s judgment
• No Hidden Fees: Transparent, flat-rate pricing at all dose levels. Plans are billed monthly on a recurring basis until you cancel. You can stop future renewals before your next billing date by emailing info@joinboca.com; once a provider has completed your review and written a prescription, cancellation requires written notice within 24 hours and a $50 professional fee applies. See Boca’s Refund Policy for full terms.

Learn more about our tirzepatide program and discuss whether it may be appropriate for you. Whether tirzepatide is right for you is a decision for you and a licensed clinician.

Related reading: Curious why some people use lower, personalized doses? Read Microdosing Semaglutide: The Honest Guide to Low-Dose, Personalized GLP-1 Care.

Frequently Asked Questions

How fast does tirzepatide work?

There is no fixed onset or monthly weight-loss schedule that this article can promise. The trial results above describe a defined study period, not when you will notice a change. Discuss progress and tolerability with your clinician; see the timeline discussion.

Is tirzepatide better than semaglutide?

In head-to-head trials of the FDA-approved branded products, tirzepatide produced greater average weight loss than semaglutide. These results apply to FDA-approved products and may not apply to compounded versions. Individual results vary based on adherence, diet, exercise, and your health history. Read our comprehensive comparison guide.

What are the most common side effects?

Nausea, diarrhea, vomiting and constipation are among the reported reactions. The trial table above gives dose-group frequencies from Zepbound studies. Symptoms and their duration vary; the table does not establish rates for compounded medication. Tirzepatide also carries an FDA boxed warning for possible thyroid C-cell tumors. See our complete side effects guide.

How much does tirzepatide cost?

Brand-name Zepbound costs roughly $1,060-1,200/month without insurance. For compounded tirzepatide (which is NOT FDA-approved), see current pricing on our compounded tirzepatide page; medical supervision is included. Insurance coverage for weight loss is very limited. See our detailed cost breakdown.

Can I take tirzepatide if I don’t have diabetes?

Zepbound is FDA-approved for weight loss in adults without diabetes who have a BMI ≥30, or BMI ≥27 with weight-related health conditions. You do not need diabetes to be considered for tirzepatide for weight loss. A licensed clinician will determine whether it is appropriate for you.

How long do I need to take tirzepatide?

Many clinicians view weight management medications as long-term treatments, but the right duration is an individual decision. Studies suggest many people regain a substantial portion of lost weight after stopping. Some people maintain weight loss on a lower “maintenance dose.” Make this decision with your healthcare provider based on your circumstances.

Is compounded tirzepatide safe?

Compounded tirzepatide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications, and clinical trial data from the branded products may not apply. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy, but compounded products are not individually FDA-approved (registration is not the same as approval). Individual results vary. Discuss the risks and benefits with your clinician. Learn more in our compounded safety guide.

Can I drink alcohol while taking tirzepatide?

Discuss alcohol use with your clinician. Alcohol may worsen nausea and gastrointestinal side effects, add empty calories that slow weight loss, and increase the risk of hypoglycemia if you have diabetes. Many people naturally lose interest in alcohol while on tirzepatide due to reduced appetite and food reward.

Will tirzepatide cause hair loss?

Hair loss was reported in Zepbound trials: 5%, 4% and 5% in the 5 mg, 10 mg and 15 mg groups, respectively, versus 1% with placebo. The prescribing information, section 6.1, describes an association with weight reduction. This does not identify the cause of hair loss in an individual or establish rates for compounded tirzepatide. Discuss new or persistent hair loss with your clinician rather than assuming a cause or starting supplements.

What happens if I miss a dose?

If you miss your weekly injection, contact your Boca clinician or pharmacist for instructions specific to your prescription before taking a late dose. Do not decide on your own whether to take it, skip it, or shift your schedule. Never double up on doses. See our complete guide on what to do if you miss a dose.

Can I take tirzepatide while pregnant or breastfeeding?

These situations require different advice. Zepbound labeling directs discontinuation when pregnancy is recognized; pregnancy planning should be discussed with your prescriber. Breastfeeding requires an individual assessment of clinical need and potential risks, not an assumption of safety from low milk levels. See the pregnancy, breastfeeding and contraception discussion above and the product label.